Companies in Translation with CIRM

2,539 views

|

July 17, 2012

  • Share
  • Alan Trounsen, President, California Institute of Regenerative Medicine (CIRM)

    Abstract
    CIRM has initiated a comprehensive translational program to begin ushering the discoveries arising from basic stem cell research into clinical application. Several of these have evolved directly from basic research into clinical trials. We have funded early translational projects that were focused on finding candidate products that could be studied for their suitability for clinical trials. We have also initiated a program of preclinical development – termed “Disease Teams” – where we have encouraged researchers and biotechnology companies to create public-private partnerships to undertake comprehensive study of candidate products (cell therapy, small molecules, biologics) that could obtain regulatory registration approval for early clinical trials within 4 years. Finally, we are supporting clinical trials for pluripotential stem cells that enables CIRM to contribute to the leading edge stem cell studies moving into application. Companies are involved in all the programs as either project leaders funded by loans or funded indirectly as partners and consultants to academic teams.

    BioengineeringStem Cells

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.